Company: PRME
Filing Date: 2025-07-02
Form Type: PRE 14A
Source: 0001193125-25-155000
Chunk: 2

Company: Prime Medicine, Inc.
Filing Date: 2025-07-02
Form: PRE 14A
Chunk 2
---
” section of the Proxy Statement that accompanies this notice for more details regarding the logistics of the virtual Special Meeting, including the ability of stockholders to submit questions during the Special Meeting, and technical details and support related to accessing the virtual platform. There is no physical location for the Special Meeting. You will not be able to attend the Special Meeting in person. Your vote is important.Whether or not you plan to attend the Special Meeting virtually and vote your shares online, it is important that your shares be represented. You may vote over the Internet, via telephone or by mail. You are urged to vote in accordance with the instructions set forth in the Proxy Materials. We encourage you to vote by proxy so that your shares will be represented and voted at the Special Meeting, whether or not you can attend. You will need the 16-digitcontrol number included on your proxy card or the instructions that accompany your proxy materials to attend the Special Meeting virtually via the Internet. Submitting your vote via the Internet or by telephone or proxy card will not affect your right to vote online during the Special Meeting. If your shares are held in “street name” (i.e., held for your account by a broker or other nominee), you will receive instructions from your broker or other nominee explaining how to vote your shares, and you will have the option to cast your vote by telephone or over the Internet if your voting instruction form from your broker or nominee includes instructions and a toll-free telephone number or Internet website to do so. In any event, to be sure that your vote will be received in time, please cast your vote by your choice of available means, at your earliest convenience. Thank you for your continued support of Prime Medicine, Inc. By Order of the Board of Directors,

| /s/ Allan Reine             |
| Allan Reine                 |
| Chief Executive Officer and 
 Director                    |
| July  , 2025                |
| Cambridge, Massachusetts    |

Table of Contents

|                                                                             |     | Page |
| Proxy Statement for 2025 Special Meeting of Stockholders                    |     |    1 |
| Important Information About the Special Meeting and Voting                  |     |    2 |
| Proposal 1 – Approval of the Repricing of Certain Outstanding Stock Options |     |    8 |
| Proposal 2 – Approval of an Adjournment of the Special                      
 Meeting                                                                     |     |   15 |
| Security Ownership of Certain Beneficial Owners and Management              |     |   16 |
| General Matters                                                             |